Analysts expect Aduhelm's launch to spur more investor interest in Alzheimer's research. See more stories on Insider's business pageIn spending more than $2 billion researching Alzheimer's disease treatments, the biotech giant Biogen made a risky bet. Rivals have racked up failure after failure in the space.Food and Drug Administration approved its Alzheimer's drug, called Aduhelm.
. For one, although Aduhelm reduced clinical trial participants' plaque levels, it wasn't clear that it stopped or even improved memory loss. Bernstein analyst Ronny Gal said that Biogen's approval opens up a path for Lilly to accelerate its donanemab plans. It may only need to show that the drug reduces plaques and succeeds in one clinical trial. FDA usually requires two successful trials.Roche also has a late-stage Alzheimer's program
Even though its research on Alzheimer's is still in the earliest stages — Prothena has yet to start human studies — Wall Street analysts said there's reason for excitement around its drug candidate. PRX012. But a reinvigoration of medical research on Alzheimer's could present new opportunities for Quanterix. It also gave the company an 11% stock price bump. Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. Biogen's drug was tested against carriers of the APOE gene, which is linked to Alzheimer's, and non-carriers.
Oh look. The BiotechIndustrialComplex makes BIG BANK for companies, executives, and investors via government action and massive taxpayer funding infusions during COVID19 InstitutionalizedCorruption SmashAndGrab